1. Field of the Invention
The present invention relates generally to an eyeglass manufacturing method using a layer with a variable index of refraction. More specifically, the present invention pertains to patient-specific spectacle lenses manufactured with an variable index aberrator in order to more accurately correct lower order aberrations and additionally correct higher order aberrations. The present invention also provides a means for correcting vision problems caused by retinal dysfunction.
2. Description of the Related Art
Present manufacturing techniques for eyeglass lenses are capable of producing lenses that correct only the lower order (sphere and cylinder) aberrations. Customarily, lens blanks are available in discrete steps of refractive power of 0.25 diopters. In most cases, these steps are too large to create optimum vision for a patient's eye.
Current manufacturing techniques do not effectively treat vision problems resulting from retinal dysfunction. For example, in macular degeneration, patients suffer from vision loss in selective areas of the fundus, typically close to the center of vision. Laser treatment of the affected areas further destroys retinal tissue, causing blindness at the treated areas. Clinical studies have shown that the human eye and brain are capable of switching to other areas of the retina to substitute the damaged area with an undamaged area. In other words, damaged areas in the retina are essentially bypassed by the brain. Ultimately, vision loss will occur as a portion of an image falls on the damaged retina. Consequently, there is a need to manufacture an eyepiece such that the image may be “warped” around the dysfunctional tissue in order to allow the entire image to focus on the remaining healthy tissue.
In light of the aforementioned problems, the need for an optical element which generates a unique wavefront phase profile becomes apparent. Traditional manufacturing methods create such profiles through grinding and polishing. Such a method of manufacture is very costly due to the amount of time and expertise required.
The present invention utilizes the technology developed by the wavefront aberrator in which a layer of variable index material, such as curable epoxy, can be sandwiched between two plane or curved glass or plastic plates. This sandwich is then exposed to the curing radiation (i.e., UV light) that is modulated spatially or temporally in order to create spatially resolved variations of refractive indices. This will allow the manufacturing of a lens that is capable of introducing or compensating for low and high order aberrations.
In the simplest form, two lens blanks are sandwiched together with a layer of epoxy such that the lenses used in conjunction approximately correct the patient's refractive spherical and cylindrical correction to within 0.25 diopters. Subsequently, the epoxy aberrator would be exposed to curing radiation in a pre-programmed way in order to fine-tune the refractive properties of the spectacle lens to the exact spherical and cylindrical prescription of the patient's eye.
Another application of the present invention is to manufacture multi-focal or progressive addition lenses constructed with a layer of variable index material sandwiched in between the two lens blanks. The drawback of progressive addition lenses today is that, like regular spectacle lenses, a true customization for a patient's eye cannot be achieved due to the current manufacturing techniques. Using the two lenses and epoxy, a customized progressive addition lens or reading lens can be manufactured by appropriately programming the curing of the epoxy aberrator.
The present invention provides an opportunity to manufacture lenses that give patients “supervision.” In order to achieve supervision, higher order aberrations of the patient's eye need to be corrected. Since these higher order aberrations, unlike the spherical and cylindrical refractive error, are highly asymmetrical, centering of the eye's optical axis with the zone of higher order correction (“supervision zone”) is important. To minimize this effect, one could devise a spectacle lens that incorporates a supervision zone only along the central optical axis, allowing the patient to achieve supervision for one or more discrete gazing angles. The remainder of the lens would then be cured to correct only the lower order aberrations. An optional transition zone could be created between the supervision zone and the normal vision zone allowing for a gradual reduction of higher order aberrations. Again, all of this would be achieved by spatially resolved programming of the epoxy aberrator's curing.
In order to cover a larger field of view with supervision, a multitude of supervision “islands” might be created. The supervision islands then are connected by transition zones that are programmed to gradually change the higher order aberrations in order to create smooth transitions.
In bifocal lenses, refractive power in discrete steps of 1 diopter is added in the lower area of the lens to aid the spectacle wearer in near distance viewing, i.e. reading. For cosmetic reasons, the visible dividing line between the distance viewing area and the reading area is disliked by many presbyobic patients. With the event of the progressive addition lens, the sharp dividing line between the distance area and the reading area has been eliminated by introducing a continuous varifocal corridor of vision with a refractive power slowly changing from the distance viewing prescription to the reading prescription.
However, due to manufacturing limitations several disadvantages exist with the progressive addition lens. First, vision through areas outside the corridor is noticeably distorted, making the progressive addition lens unsuitable for many patients. Second, while the patient's individual prescription is applied to the distance viewing area, the added refractive power for the reading area is only offered in discrete steps of 1 diopter. Third, the distance between the centers of the distance viewing and reading viewing areas is fixed by the lens design and cannot be changed to accommodate for an individual's preference or application. Furthermore, the corridor design is fixed for any particular brand of lens and cannot be changed according to the patient's actual viewing preferences or spectacle frame selected.
Therefore, when prescribing a progressive addition lens, the eye care professional has to choose from an assortment of designs and manufacturers of the lens which matches the requirements of the patient most closely. The present invention allows one to manufacture a lens that is entirely customized and optimized to the patient's individual requirements.
Lastly, the present invention may be used to “warp” the retinal image so that damaged portions of the retina will be bypassed by the image. In order to do this, the visual field of the patient needs to be mapped with a perimeter or micro-perimeter. From this map of healthy retina, spectacle lenses could be manufactured using the epoxy aberrator.
The novel features of this invention, as well as the invention itself, both as to its structure and its operation, will be best understood from the accompanying drawings, taken in conjunction with the accompanying description, in which like reference characters refer to similar parts, and in which:
Referring initially to
The variable index layer 103 makes up the normal vision zone 106, the transition zone 110, and the supervision zone 108, where the epoxy at each zone is cured to a specific index of refraction. The normal vision zone 106 corrects the lower order spherical and cylindrical aberrations of the patient's eye. The transition zone 110 allows for a gradual reduction of higher order aberrations. The supervision zone 108 lies along the patient's optical axis (not shown) and corrects the higher order aberrations allowing the patient to achieve supervision for one or more discrete gazing angles. The shape of the lens 100 is meant to be exemplary of the shape of a typical eyeglass lens, and any shape, including highly curved lenses, may be used while not departing from the present invention.
Referring now to
Referring now to
Referring now to
Referring now to
Referring now to
One special application of this invention is the use for correcting vision problems caused by retinal dysfunction, e.g., by eye diseases like glaucoma or macular degeneration.
While the different embodiments of the present invention as herein shown and disclosed in detail is fully capable of obtaining the objects and providing the advantages herein before stated, it is to be understood that it is merely illustrative of a preferred embodiment and an alternative embodiment of the invention and that no limitations are intended to the details of construction or design herein shown other than as described in the appended claims.
This application is a continuation of U.S. patent application Ser. No. 11/703,855, filed on Feb. 7, 2007, which is a continuation of U.S. patent application Ser. No. 11/649,995, filed Jan. 5, 2007, which is a continuation of U.S. patent application Ser. No. 11/338,090, filed Jan. 24, 2006, which is a continuation of U.S. patent application Ser. No. 10/946,384, filed Sep. 20, 2004, now U.S. Pat. No. 7,021,764, which is a divisional of U.S. patent application Ser. No. 10/773,667, filed Feb. 6, 2004, now U.S. Pat. No. 6,840,619, which is a continuation of U.S. patent application Ser. No. 10/044,304, filed Oct. 25, 2001, now U.S. Pat. No. 6,712,466, all of which are hereby incorporated by reference in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
3485556 | Naujokas | Dec 1969 | A |
3718383 | Moore | Feb 1973 | A |
3933411 | Winner | Jan 1976 | A |
3973837 | Page | Aug 1976 | A |
4022855 | Hamblen | May 1977 | A |
4257988 | Matos et al. | Mar 1981 | A |
4268133 | Fischer et al. | May 1981 | A |
4422733 | Kikuchi et al. | Dec 1983 | A |
4666236 | Mikami et al. | May 1987 | A |
4711576 | Ban | Dec 1987 | A |
4778256 | Serizawa | Oct 1988 | A |
4810070 | Suda et al. | Mar 1989 | A |
4869587 | Breger | Sep 1989 | A |
4874234 | Wichterle | Oct 1989 | A |
4883548 | Onoki | Nov 1989 | A |
4944584 | Maeda et al. | Jul 1990 | A |
4969729 | Merle | Nov 1990 | A |
4996123 | Nomura et al. | Feb 1991 | A |
5033838 | Bonbon et al. | Jul 1991 | A |
5062702 | Bille | Nov 1991 | A |
5080472 | Gupta | Jan 1992 | A |
5080477 | Adachi | Jan 1992 | A |
5100589 | Ticknor | Mar 1992 | A |
5114628 | Hofer et al. | May 1992 | A |
5116684 | Fretz, Jr. et al. | May 1992 | A |
5148205 | Guilino et al. | Sep 1992 | A |
5157746 | Tobita et al. | Oct 1992 | A |
5164750 | Adachi | Nov 1992 | A |
5198844 | Roffman et al. | Mar 1993 | A |
5229797 | Futhey et al. | Jul 1993 | A |
5266352 | Filas et al. | Nov 1993 | A |
5276693 | Long et al. | Jan 1994 | A |
5296305 | Baude et al. | Mar 1994 | A |
5343260 | Henry et al. | Aug 1994 | A |
5372755 | Stoerr et al. | Dec 1994 | A |
5433810 | Abrams | Jul 1995 | A |
5448312 | Roffman et al. | Sep 1995 | A |
5512371 | Gupta et al. | Apr 1996 | A |
5528321 | Blum et al. | Jun 1996 | A |
5531940 | Gupta et al. | Jul 1996 | A |
5585968 | Guhman et al. | Dec 1996 | A |
5606378 | Van Meurs | Feb 1997 | A |
5608471 | Miller | Mar 1997 | A |
5617154 | Hoffman | Apr 1997 | A |
5638479 | Takami et al. | Jun 1997 | A |
5650837 | Roffman et al. | Jul 1997 | A |
5715031 | Roffman et al. | Feb 1998 | A |
5771088 | Perrott | Jun 1998 | A |
5777719 | Williams et al. | Jul 1998 | A |
5786883 | Miller et al. | Jul 1998 | A |
5835192 | Roffman et al. | Nov 1998 | A |
5861934 | Blum et al. | Jan 1999 | A |
5864379 | Dunn | Jan 1999 | A |
5872613 | Blum et al. | Feb 1999 | A |
5880809 | Lieberman et al. | Mar 1999 | A |
5929969 | Roffman | Jul 1999 | A |
5949521 | Williams et al. | Sep 1999 | A |
5953098 | Lieberman et al. | Sep 1999 | A |
5956183 | Epstein et al. | Sep 1999 | A |
5963300 | Horwitz | Oct 1999 | A |
5986818 | Hashimura | Nov 1999 | A |
5998096 | Umemoto et al. | Dec 1999 | A |
6007204 | Fahrenkrug et al. | Dec 1999 | A |
6010756 | Gasworth | Jan 2000 | A |
6028723 | Smith | Feb 2000 | A |
6050687 | Bille et al. | Apr 2000 | A |
6070979 | Kagei et al. | Jun 2000 | A |
6081632 | Yoshimura et al. | Jun 2000 | A |
6086204 | Magnante | Jul 2000 | A |
6089711 | Blankenbecler et al. | Jul 2000 | A |
6095651 | Williams et al. | Aug 2000 | A |
6109749 | Bernstein | Aug 2000 | A |
6112114 | Dreher | Aug 2000 | A |
6120150 | Sarver et al. | Sep 2000 | A |
6155684 | Bille et al. | Dec 2000 | A |
6176580 | Roffman et al. | Jan 2001 | B1 |
6199986 | Williams et al. | Mar 2001 | B1 |
6224211 | Gordon | May 2001 | B1 |
6234631 | Sarver et al. | May 2001 | B1 |
6240226 | Presby et al. | May 2001 | B1 |
6256098 | Rubinstein et al. | Jul 2001 | B1 |
6257723 | Sarver et al. | Jul 2001 | B1 |
6270221 | Liang et al. | Aug 2001 | B1 |
6271915 | Frey et al. | Aug 2001 | B1 |
6274288 | Kewitsch et al. | Aug 2001 | B1 |
6299311 | Williams et al. | Oct 2001 | B1 |
6305802 | Roffman et al. | Oct 2001 | B1 |
6319433 | Kohan | Nov 2001 | B1 |
6338559 | Williams et al. | Jan 2002 | B1 |
6379005 | Williams et al. | Apr 2002 | B1 |
6379008 | Chateau et al. | Apr 2002 | B1 |
6382795 | Lai | May 2002 | B1 |
6394605 | Campin et al. | May 2002 | B1 |
6396588 | Sei | May 2002 | B1 |
6464355 | Gil | Oct 2002 | B1 |
6499843 | Cox et al. | Dec 2002 | B1 |
6721043 | Platt et al. | Apr 2004 | B2 |
6786599 | Hayashi | Sep 2004 | B2 |
6786602 | Abitbol | Sep 2004 | B2 |
6813082 | Bruns | Nov 2004 | B2 |
6830712 | Roffman et al. | Dec 2004 | B1 |
6840752 | Foreman et al. | Jan 2005 | B2 |
6917416 | Platt et al. | Jul 2005 | B2 |
7021764 | Dreher | Apr 2006 | B2 |
7188950 | Dreher et al. | Mar 2007 | B2 |
20010033362 | Sarver | Oct 2001 | A1 |
20010035939 | Mihashi et al. | Nov 2001 | A1 |
20010041884 | Frey et al. | Nov 2001 | A1 |
20020047992 | Graves et al. | Apr 2002 | A1 |
20020080464 | Bruns | Jun 2002 | A1 |
20020196412 | Abitbol | Dec 2002 | A1 |
20030128330 | Iori et al. | Jul 2003 | A1 |
20040008319 | Lai et al. | Jan 2004 | A1 |
20040051846 | Blum et al. | Mar 2004 | A1 |
20060119792 | Dreher | Jun 2006 | A1 |
Number | Date | Country |
---|---|---|
0 077 168 | Mar 1986 | EP |
0 340 091 | Nov 1989 | EP |
0 472 384 | Aug 1991 | EP |
0 949 529 | Apr 1999 | EP |
1411976 | Sep 1965 | FR |
2 661 914 | Nov 1991 | FR |
1163002 | Sep 1969 | GB |
57-046202 | Mar 1982 | JP |
57-201216 | Dec 1982 | JP |
60-175009 | Sep 1985 | JP |
WO-9201417 | Jun 1992 | WO |
WO-9321010 | Oct 1993 | WO |
WO-9738344 | Oct 1997 | WO |
WO-9827863 | Jul 1998 | WO |
WO-9853360 | Nov 1998 | WO |
WO-9913361 | Mar 1999 | WO |
WO-0019885 | Apr 2000 | WO |
WO-0041650 | Jul 2000 | WO |
WO-0102896 | Jan 2001 | WO |
WO-0147449 | Jul 2001 | WO |
WO-0161382 | Aug 2001 | WO |
WO-0171411 | Sep 2001 | WO |
WO-0182791 | Nov 2001 | WO |
WO-0189424 | Nov 2001 | WO |
WO-0209579 | Feb 2002 | WO |
WO-0219901 | Mar 2002 | WO |
WO-0228272 | Apr 2002 | WO |
WO-0230273 | Apr 2002 | WO |
WO-0232297 | Apr 2002 | WO |
Number | Date | Country | |
---|---|---|---|
20080218688 A1 | Sep 2008 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10773667 | Feb 2004 | US |
Child | 10946384 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11703855 | Feb 2007 | US |
Child | 12048169 | US | |
Parent | 11649995 | Jan 2007 | US |
Child | 11703855 | US | |
Parent | 11338090 | Jan 2006 | US |
Child | 11649995 | US | |
Parent | 10946384 | Sep 2004 | US |
Child | 11338090 | US | |
Parent | 10044304 | Oct 2001 | US |
Child | 10773667 | US |